Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SCO1 (ImmuneEditome ID:6341)

1. Gene summary of enriched editing regions for SCO1

Gene summary

Gene information	Gene symbol	SCO1
	Gene ID	6341
	GeneSynonyms	MC4DN4\|SCOD1
	GeneCytomap	17p13.1
	GeneType	protein-coding
	GeneDescription	protein SCO1 homolog, mitochondrial\|SCO cytochrome c oxidase assembly protein 1\|SCO cytochrome oxidase deficient homolog 1\|SCO1, cytochrome c oxidase assembly protein
	GeneModificationdate	20230329
	UniprotID	O75880;J3QL56;J3QR42
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr17:10673040-10674413:-	ENST00000255390.8	ENSG00000133028.9	SCO1	UTR3	AluSq,Charlie19a,MER5A1,AluSc	chr17:10673040-10674413:-.alignment
chr17:10676095-10680081:-	ENST00000255390.8	ENSG00000133028.9	SCO1	UTR3	AluSp,AluSx1,MLT1B,L1MC5a,AluJr4	chr17:10676095-10680081:-.alignment

Top

2. Tumor-specific enriched editing regions for SCO1

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr17:10673040-10674413:-	BRCA	EER	2.2134e-02
ENSG00000133028.9,SCO1	BRCA	EAG	1.2254e-03
chr17:10673040-10674413:-	COAD	EER	2.5782e-02
ENSG00000133028.9,SCO1	KICH	EAG	7.9725e-03
ENSG00000133028.9,SCO1	KIRC	EAG	6.7375e-03
chr17:10676095-10680081:-	KIRP	EER	2.4220e-02
ENSG00000133028.9,SCO1	KIRP	EAG	2.9973e-03
chr17:10673040-10674413:-	LIHC	EER	4.2490e-02
ENSG00000133028.9,SCO1	LIHC	EAG	1.8510e-02
chr17:10676095-10680081:-	LUSC	EER	3.3001e-02
chr17:10676095-10680081:-	PRAD	EER	4.5363e-02
chr17:10673040-10674413:-	THCA	EER	1.2549e-02
ENSG00000133028.9,SCO1	THCA	EAG	4.1742e-04

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

StageType

AnovaP

Boxplot

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr17:10676095-10680081:-	LIHC	EER	2.0591e-02	1.1845e-02	2.0056e+05
ENSG00000133028.9,SCO1	LUSC	EAG	4.8258e-02	1.5909e-02	8.4872e-02
chr17:10673040-10674413:-	UCEC	EER	7.9899e-03	5.6093e-03	3.7400e+02
ENSG00000133028.9,SCO1	UCEC	EAG	3.9266e-03	2.5064e-03	2.1039e+03

Top

3. Enriched editing regions and immune related genes for SCO1

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for SCO1

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr17:10676095-10680081:-

ESCA

EER

ENSG00000004700.11

chr12

21468910:21470884:21470968:21471098

-0.2841

2.6458e-02

6.3410e-07

-0.4297

TAF15

chr17:10676095-10680081:-

ESCA

EER

ENSG00000130770.13

chr1

28236341:28236452:28237695:28238098

-0.4019

4.8113e-03

9.3952e-10

-0.5132

TAF15

T_cells_CD8

ENSG00000133028.9,SCO1

ESCA

EAG

ENSG00000147454.9

chr8

23568321:23568378:23566107:23566336:23566107:23566813

-0.3669

4.2943e-03

1.2994e-07

-0.4311

ACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RC3H1;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

T_cells_gamma_delta

GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE

ENSG00000133028.9,SCO1

GBM

EAG

MEX

ENSG00000004142.7

chr17

28349082:28349162:28349323:28349453:28349496:28349626:28350437:28350563

0.1649

4.7470e-02

4.3202e-06

0.4024

ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

B_cells_memory

GSVA_HALLMARK_NOTCH_SIGNALING

ENSG00000133028.9,SCO1

TGCT

EAG

MEX

ENSG00000129657.10

chr17

77213917:77215753:77215792:77215805:77215818:77216075:77216127:77216153

-0.3267

8.2713e-03

1.9232e-05

-0.4022

ACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RC3H1;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

B_cells_memory

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000133028.9,SCO1

TGCT

EAG

MEX

ENSG00000129657.10

chr17

77216062:77216075:77216127:77216231:77216231:77216296:77216335:77216348

0.3022

9.1248e-03

5.6993e-05

0.4177

Mast_cells_resting

GSVA_HALLMARK_ALLOGRAFT_REJECTION

ENSG00000133028.9,SCO1

TGCT

EAG

MEX

ENSG00000129657.10

chr17

77213917:77215753:77215792:77215818:77215818:77216075:77216127:77216140

-0.3262

8.4354e-03

1.9443e-05

-0.4020

B_cells_memory

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000133028.9,SCO1

TGCT

EAG

MEX

ENSG00000129657.10

chr17

77213917:77215753:77215792:77215805:77215870:77216075:77216127:77216153

-0.3245

9.1957e-03

9.6802e-06

-0.4169

B_cells_memory

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000133028.9,SCO1

TGCT

EAG

MEX

ENSG00000129657.10

chr17

77213917:77215753:77215792:77215870:77215870:77216075:77216127:77216153

-0.3245

9.1957e-03

9.6802e-06

-0.4169

B_cells_memory

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000133028.9,SCO1

TGCT

EAG

ENSG00000153406.9

chr16

4461679:4461959:4463419:4463512

-0.3646

1.0992e-02

7.3522e-06

-0.4078

ACIN1;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184

Macrophages_M2

GSVA_HALLMARK_MITOTIC_SPINDLE

More results

Top

5. Enriched editing regions and immune infiltration for SCO1

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr17:10673040-10674413:-	BLCA	EER	T_cells_CD4_naive	4.1663e-02	-0.1578
ENSG00000133028.9,SCO1	BLCA	EAG	B_cells_naive	1.8139e-02	0.1779
ENSG00000133028.9,SCO1	BRCA	EAG	T_cells_regulatory_(Tregs)	3.0524e-02	0.0861
chr17:10673040-10674413:-	COAD	EER	Neutrophils	1.6817e-02	0.1888
chr17:10673040-10674413:-	GBM	EER	Monocytes	7.3921e-03	0.2263
ENSG00000133028.9,SCO1	GBM	EAG	Monocytes	8.3134e-03	0.2222
chr17:10673040-10674413:-	HNSC	EER	T_cells_CD4_naive	2.4440e-02	0.1901
ENSG00000133028.9,SCO1	HNSC	EAG	NK_cells_activated	4.6325e-03	0.2131
chr17:10673040-10674413:-	KICH	EER	Macrophages_M0	2.3489e-02	0.2898
ENSG00000133028.9,SCO1	KICH	EAG	Macrophages_M0	1.3367e-02	0.3126
chr17:10676095-10680081:-	KIRC	EER	T_cells_follicular_helper	6.0845e-03	-0.2341
ENSG00000133028.9,SCO1	KIRC	EAG	NK_cells_activated	2.6491e-02	0.1317
chr17:10673040-10674413:-	KIRP	EER	Plasma_cells	6.6832e-03	0.1732
chr17:10676095-10680081:-	KIRP	EER	T_cells_CD4_memory_activated	3.5336e-05	0.3836
ENSG00000133028.9,SCO1	KIRP	EAG	Plasma_cells	7.2617e-03	0.1708
ENSG00000133028.9,SCO1	LAML	EAG	Mast_cells_resting	2.5082e-02	-0.2012
chr17:10673040-10674413:-	LGG	EER	B_cells_memory	9.3111e-03	0.1201
ENSG00000133028.9,SCO1	LGG	EAG	B_cells_memory	1.2468e-03	0.1472
chr17:10673040-10674413:-	LIHC	EER	Dendritic_cells_activated	1.6149e-03	0.2249
chr17:10676095-10680081:-	LIHC	EER	Dendritic_cells_activated	1.4460e-02	0.4219
ENSG00000133028.9,SCO1	LIHC	EAG	Dendritic_cells_activated	6.1528e-04	0.2395
chr17:10673040-10674413:-	LUAD	EER	Mast_cells_activated	2.8750e-02	0.1649
ENSG00000133028.9,SCO1	LUAD	EAG	Mast_cells_resting	1.7067e-02	0.1698
chr17:10676095-10680081:-	LUSC	EER	Eosinophils	2.6427e-02	0.2842
ENSG00000133028.9,SCO1	LUSC	EAG	Neutrophils	4.7564e-02	0.1569
chr17:10673040-10674413:-	OV	EER	NK_cells_resting	1.7874e-02	-0.1497
ENSG00000133028.9,SCO1	OV	EAG	NK_cells_resting	1.6014e-02	-0.1513
chr17:10673040-10674413:-	PCPG	EER	T_cells_CD8	2.2328e-02	-0.2585
ENSG00000133028.9,SCO1	PCPG	EAG	T_cells_CD8	3.7472e-02	-0.2248
chr17:10673040-10674413:-	PRAD	EER	Monocytes	2.8764e-02	-0.1230
chr17:10676095-10680081:-	PRAD	EER	Neutrophils	3.9210e-02	-0.1840
chr17:10673040-10674413:-	READ	EER	Eosinophils	4.9930e-02	0.2682
chr17:10673040-10674413:-	SARC	EER	Eosinophils	9.5919e-04	0.2874
chr17:10676095-10680081:-	SARC	EER	Neutrophils	1.7082e-05	0.6585
ENSG00000133028.9,SCO1	SARC	EAG	Eosinophils	2.9800e-04	0.3123
chr17:10676095-10680081:-	SKCM	EER	Neutrophils	2.2778e-04	0.3431
ENSG00000133028.9,SCO1	SKCM	EAG	Macrophages_M2	3.1733e-02	-0.1405
chr17:10673040-10674413:-	STAD	EER	Eosinophils	8.1910e-04	0.1799
chr17:10676095-10680081:-	STAD	EER	NK_cells_activated	4.3025e-03	0.1698
ENSG00000133028.9,SCO1	STAD	EAG	Eosinophils	1.6595e-03	0.1673
chr17:10673040-10674413:-	TGCT	EER	T_cells_CD4_naive	1.9093e-02	0.2222
chr17:10673040-10674413:-	THCA	EER	Dendritic_cells_activated	2.0129e-02	0.1273
ENSG00000133028.9,SCO1	THCA	EAG	Monocytes	4.5101e-02	-0.1084
ENSG00000133028.9,SCO1	THYM	EAG	T_cells_CD8	1.6535e-02	0.2836
ENSG00000133028.9,SCO1	UVM	EAG	T_cells_follicular_helper	3.9862e-02	0.4136

Top

6. Enriched editing regions and immune gene sets for SCO1

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr17:10673040-10674413:-	ACC	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EER	1.5603e-02	0.3666
ENSG00000133028.9,SCO1	ACC	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EAG	1.9822e-02	0.3541
ENSG00000133028.9,SCO1	BLCA	GSVA_HALLMARK_ANGIOGENESIS	EAG	1.9848e-02	0.1755
chr17:10673040-10674413:-	BLCA	GSVA_HALLMARK_ANGIOGENESIS	EER	1.5486e-02	0.1871
chr17:10676095-10680081:-	BLCA	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	4.9505e-02	0.3252
chr17:10676095-10680081:-	BRCA	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EER	1.5905e-03	0.1661
chr17:10673040-10674413:-	BRCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.4177e-02	0.1065
ENSG00000133028.9,SCO1	BRCA	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.1581e-06	-0.1920
ENSG00000133028.9,SCO1	CESC	GSVA_HALLMARK_KRAS_SIGNALING_UP	EAG	1.8432e-02	0.1955
chr17:10673040-10674413:-	CESC	GSVA_HALLMARK_KRAS_SIGNALING_UP	EER	9.8216e-03	0.2168
chr17:10673040-10674413:-	CHOL	GSVA_HALLMARK_G2M_CHECKPOINT	EER	6.2456e-03	0.5641
ENSG00000133028.9,SCO1	CHOL	GSVA_HALLMARK_E2F_TARGETS	EAG	6.8608e-03	0.5474
ENSG00000133028.9,SCO1	COAD	GSVA_HALLMARK_HYPOXIA	EAG	2.8583e-03	0.2268
chr17:10673040-10674413:-	COAD	GSVA_HALLMARK_APOPTOSIS	EER	1.6969e-04	0.2930
ENSG00000133028.9,SCO1	DLBC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	1.8895e-02	0.4408
ENSG00000133028.9,SCO1	ESCA	GSVA_HALLMARK_HYPOXIA	EAG	4.8831e-03	0.2236
chr17:10673040-10674413:-	ESCA	GSVA_HALLMARK_HYPOXIA	EER	8.7860e-04	0.2654
ENSG00000133028.9,SCO1	GBM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	3.5148e-03	0.2451
chr17:10673040-10674413:-	GBM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	2.1255e-03	0.2585
ENSG00000133028.9,SCO1	HNSC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	4.0952e-04	-0.2643
chr17:10673040-10674413:-	HNSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	8.3405e-03	0.2222
ENSG00000133028.9,SCO1	KICH	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	1.4840e-02	-0.3081
chr17:10673040-10674413:-	KICH	GSVA_HALLMARK_UV_RESPONSE_UP	EER	4.2891e-02	-0.2602
ENSG00000133028.9,SCO1	KIRC	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	4.4177e-04	0.2072
chr17:10673040-10674413:-	KIRC	GSVA_HALLMARK_UV_RESPONSE_UP	EER	4.0298e-04	0.2182
chr17:10673040-10674413:-	KIRP	GSVA_HALLMARK_COAGULATION	EER	4.0289e-04	0.2248
ENSG00000133028.9,SCO1	KIRP	GSVA_HALLMARK_COAGULATION	EAG	1.6674e-02	0.1525
chr17:10676095-10680081:-	KIRP	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	2.1447e-05	-0.3932
chr17:10673040-10674413:-	LAML	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	2.5573e-03	0.2719
chr17:10676095-10680081:-	LAML	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	4.0729e-02	0.3098
ENSG00000133028.9,SCO1	LAML	GSVA_HALLMARK_IL2_STAT5_SIGNALING	EAG	8.5647e-04	0.2957
chr17:10676095-10680081:-	LGG	GSVA_HALLMARK_HEME_METABOLISM	EER	8.0105e-03	0.1939
chr17:10673040-10674413:-	LGG	GSVA_HALLMARK_MYOGENESIS	EER	5.1303e-04	0.1600
ENSG00000133028.9,SCO1	LGG	GSVA_HALLMARK_ADIPOGENESIS	EAG	7.5909e-06	0.2031
ENSG00000133028.9,SCO1	LIHC	GSVA_HALLMARK_DNA_REPAIR	EAG	9.6462e-03	-0.1822
chr17:10673040-10674413:-	LIHC	GSVA_HALLMARK_DNA_REPAIR	EER	1.5702e-02	-0.1733
chr17:10673040-10674413:-	LUAD	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.1223e-02	0.1907
ENSG00000133028.9,SCO1	OV	GSVA_HALLMARK_PEROXISOME	EAG	4.6904e-02	0.1251
chr17:10673040-10674413:-	PAAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	2.2775e-02	0.3550
ENSG00000133028.9,SCO1	PCPG	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EAG	2.2344e-02	-0.2461
ENSG00000133028.9,SCO1	PRAD	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	1.7873e-03	0.1708
chr17:10676095-10680081:-	PRAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	3.0749e-02	-0.1926
chr17:10673040-10674413:-	PRAD	GSVA_HALLMARK_PROTEIN_SECRETION	EER	3.9299e-03	0.1618
chr17:10673040-10674413:-	READ	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	6.3119e-05	0.5168
ENSG00000133028.9,SCO1	READ	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	1.1361e-03	0.4274
chr17:10676095-10680081:-	SARC	GSVA_HALLMARK_HYPOXIA	EER	2.6178e-04	0.5798
chr17:10673040-10674413:-	SARC	GSVA_HALLMARK_PEROXISOME	EER	2.3979e-02	0.1987
ENSG00000133028.9,SCO1	SARC	GSVA_HALLMARK_PEROXISOME	EAG	2.7387e-02	0.1935
ENSG00000133028.9,SCO1	SKCM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	7.0573e-03	0.1757
chr17:10673040-10674413:-	SKCM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.2517e-02	0.1741
ENSG00000133028.9,SCO1	STAD	GSVA_HALLMARK_DNA_REPAIR	EAG	1.5474e-02	0.1291
chr17:10676095-10680081:-	STAD	GSVA_HALLMARK_UV_RESPONSE_DN	EER	2.3257e-02	-0.1353
chr17:10673040-10674413:-	STAD	GSVA_HALLMARK_APOPTOSIS	EER	1.8838e-04	0.2003
ENSG00000133028.9,SCO1	TGCT	GSVA_HALLMARK_G2M_CHECKPOINT	EAG	1.3185e-04	-0.3476
chr17:10673040-10674413:-	TGCT	GSVA_HALLMARK_G2M_CHECKPOINT	EER	1.4991e-03	-0.2978
chr17:10673040-10674413:-	THCA	GSVA_HALLMARK_APOPTOSIS	EER	3.3647e-04	0.1953
ENSG00000133028.9,SCO1	THCA	GSVA_HALLMARK_COAGULATION	EAG	2.4656e-04	0.1970
chr17:10673040-10674413:-	UCEC	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	1.4422e-02	0.3170
ENSG00000133028.9,SCO1	UCEC	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	1.1844e-02	0.3178
chr17:10673040-10674413:-	UCS	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	1.9408e-02	0.4391
ENSG00000133028.9,SCO1	UCS	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	2.3852e-02	0.4259

Top

7. Enriched editing regions and drugs for SCO1

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr17:10673040-10674413:-	ACC	AZD.2281	EER	1.5784e-02	-0.3660
ENSG00000133028.9,SCO1	ACC	AZD.2281	EAG	1.1733e-02	-0.3809
chr17:10673040-10674413:-	BLCA	JW.7.52.1	EER	1.7999e-02	0.1829
ENSG00000133028.9,SCO1	BLCA	GDC0941	EAG	4.9673e-02	-0.1482
chr17:10676095-10680081:-	BRCA	Bryostatin.1	EER	6.6073e-04	-0.1792
chr17:10673040-10674413:-	BRCA	Lenalidomide	EER	2.1271e-03	0.1332
ENSG00000133028.9,SCO1	BRCA	ATRA	EAG	7.4658e-06	0.1774
ENSG00000133028.9,SCO1	CESC	GW843682X	EAG	1.0703e-02	0.2114
chr17:10673040-10674413:-	CESC	GW843682X	EER	5.3517e-03	0.2334
chr17:10673040-10674413:-	CHOL	AZD.2281	EER	1.6092e-03	0.6446
ENSG00000133028.9,SCO1	CHOL	AZD.2281	EAG	5.4636e-05	0.7519
ENSG00000133028.9,SCO1	COAD	BIRB.0796	EAG	2.9209e-02	0.1668
chr17:10673040-10674413:-	COAD	Bortezomib	EER	1.0343e-02	-0.2022
ENSG00000133028.9,SCO1	ESCA	CGP.60474	EAG	2.4174e-02	-0.1799
chr17:10673040-10674413:-	ESCA	Bexarotene	EER	2.6809e-03	-0.2403
chr17:10673040-10674413:-	GBM	EHT.1864	EER	8.4173e-03	0.2227
ENSG00000133028.9,SCO1	GBM	CGP.082996	EAG	1.1416e-02	-0.2133
chr17:10676095-10680081:-	HNSC	Bryostatin.1	EER	4.5488e-02	-0.2301
ENSG00000133028.9,SCO1	HNSC	GW843682X	EAG	6.9199e-05	-0.2961
chr17:10673040-10674413:-	HNSC	Gefitinib	EER	1.1420e-03	-0.2731
chr17:10673040-10674413:-	KICH	Bosutinib	EER	5.5985e-03	-0.3506
ENSG00000133028.9,SCO1	KICH	JNJ.26854165	EAG	1.7509e-02	-0.3008
ENSG00000133028.9,SCO1	KIRC	GSK269962A	EAG	3.1228e-08	-0.3211
chr17:10673040-10674413:-	KIRC	GNF.2	EER	3.3682e-05	-0.2547
chr17:10676095-10680081:-	KIRC	GDC.0449	EER	4.8453e-02	-0.1695
ENSG00000133028.9,SCO1	KIRP	EHT.1864	EAG	6.1170e-06	0.2838
chr17:10676095-10680081:-	KIRP	AS601245	EER	9.6535e-05	0.3631
chr17:10673040-10674413:-	KIRP	DMOG	EER	5.7307e-06	-0.2858
chr17:10676095-10680081:-	LAML	AZD6482	EER	8.0433e-03	0.3946
ENSG00000133028.9,SCO1	LAML	Dasatinib	EAG	6.2284e-07	-0.4300
chr17:10673040-10674413:-	LAML	Dasatinib	EER	9.3181e-05	-0.3477
chr17:10673040-10674413:-	LGG	JNK.Inhibitor.VIII	EER	1.2211e-04	0.1767
ENSG00000133028.9,SCO1	LGG	JNK.Inhibitor.VIII	EAG	5.8580e-06	0.2056
chr17:10676095-10680081:-	LIHC	Cytarabine	EER	7.2624e-03	-0.4587
ENSG00000133028.9,SCO1	LIHC	Doxorubicin	EAG	2.7751e-02	0.1553
chr17:10673040-10674413:-	LUAD	BMS.754807	EER	4.0976e-02	-0.1542
chr17:10676095-10680081:-	LUAD	Metformin	EER	9.5259e-03	0.3294
ENSG00000133028.9,SCO1	LUSC	Methotrexate	EAG	4.0234e-02	-0.1634
chr17:10673040-10674413:-	LUSC	FTI.277	EER	1.7576e-02	-0.2012
chr17:10676095-10680081:-	LUSC	Bleomycin	EER	8.0645e-03	0.3362
chr17:10673040-10674413:-	MESO	CMK	EER	2.0770e-02	-0.3788
chr17:10673040-10674413:-	OV	AICAR	EER	1.4428e-04	0.2381
ENSG00000133028.9,SCO1	OV	AICAR	EAG	1.8069e-03	0.1952
chr17:10676095-10680081:-	OV	BMS.708163	EER	1.9681e-02	-0.2744
ENSG00000133028.9,SCO1	PAAD	MG.132	EAG	2.5297e-02	-0.3261
ENSG00000133028.9,SCO1	PCPG	A.443654	EAG	3.6181e-02	-0.2263
ENSG00000133028.9,SCO1	PRAD	Lenalidomide	EAG	2.4990e-02	0.1230
chr17:10673040-10674413:-	PRAD	KU.55933	EER	1.0265e-02	0.1442
chr17:10676095-10680081:-	PRAD	LFM.A13	EER	1.0911e-02	-0.2261
chr17:10673040-10674413:-	READ	Embelin	EER	3.8143e-04	-0.4662
ENSG00000133028.9,SCO1	READ	Elesclomol	EAG	7.5457e-04	0.4409
chr17:10676095-10680081:-	SARC	Bryostatin.1	EER	2.9014e-03	-0.4886
ENSG00000133028.9,SCO1	SARC	Cisplatin	EAG	1.5430e-02	-0.2121
chr17:10673040-10674413:-	SARC	BIRB.0796	EER	2.6931e-02	-0.1948
chr17:10673040-10674413:-	SKCM	BMS.708163	EER	6.2375e-03	-0.1904
chr17:10676095-10680081:-	SKCM	Metformin	EER	1.4624e-02	-0.2312
ENSG00000133028.9,SCO1	SKCM	CEP.701	EAG	2.9066e-03	-0.1938
chr17:10676095-10680081:-	STAD	GW.441756	EER	1.2105e-02	-0.1495
ENSG00000133028.9,SCO1	STAD	GW.441756	EAG	2.5091e-04	-0.1943
chr17:10676095-10680081:-	TGCT	GW.441756	EER	4.8888e-02	0.2719
chr17:10673040-10674413:-	TGCT	GDC0941	EER	1.9996e-02	-0.2206
ENSG00000133028.9,SCO1	TGCT	CI.1040	EAG	1.4339e-02	-0.2268
chr17:10673040-10674413:-	THCA	AZD8055	EER	9.2520e-04	0.1807
ENSG00000133028.9,SCO1	THCA	LFM.A13	EAG	1.2921e-03	-0.1733
chr17:10673040-10674413:-	UCS	Elesclomol	EER	2.4770e-03	-0.5491
ENSG00000133028.9,SCO1	UCS	Elesclomol	EAG	3.2602e-03	-0.5363
ENSG00000133028.9,SCO1	UVM	GDC0941	EAG	2.5348e-03	-0.5769

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER	ENST	UniprotID	DrugBankID	Drug	DrugType
chr17:10673040-10674413:-	ENST00000255390.8	O75880	DB09130	Copper	SmallMoleculeDrug
chr17:10676095-10680081:-	ENST00000255390.8	O75880	DB09130	Copper	SmallMoleculeDrug